Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01124019 · ClinicalTrials.gov registry record
Single Nucleotide Polymorphism (SNP) Panels and Risk Assessment in Women Undergoing Mammography
A clinical trial, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- 1,600
- Enrollment target
NCT01124019 is a clinical trial that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 1,600 participants.
The verdict
NCT01124019 has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- 1,600 participants
- Enrollment target
Study Summary
The primary objective is to compare the predicted lifetime risk values produced by SNP panel assessment to the risk values produced by the prediction models that are most commonly used. A second objective is to examine whether the incorporation of risk assessment panels (standard or SNP based) can improve the positive value of breast biopsies in women with BIRADS 4 mammograms.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,600 participants |
| Start Date | 2010-02 |
| Est. Completion | 2012-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01124019
The ClinicalTrials.gov registry entry for NCT01124019 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,600 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01124019 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01124019 about?
NCT01124019 is a clinical study titled "Single Nucleotide Polymorphism (SNP) Panels and Risk Assessment in Women Undergoing Mammography". The primary objective is to compare the predicted lifetime risk values produced by SNP panel assessment to the risk values produced by the prediction models that are most commonly used. A second objective is to examine whether the incorporation of risk assessment panels (standard or SNP based) can i...
What is the current status of trial NCT01124019?
This trial is currently completed. The enrollment target is 1,600 participants. The study started on 2010-02. Estimated completion is 2012-10.
Who is sponsoring clinical trial NCT01124019?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.